MARKET

XOMAP

XOMAP

XOMA Royalty Corporation
NASDAQ
26.12
+0.15
+0.58%
Closed 12:28 02/12 EST
OPEN
26.00
PREV CLOSE
25.97
HIGH
26.12
LOW
26.00
VOLUME
613
TURNOVER
--
52 WEEK HIGH
28.80
52 WEEK LOW
23.47
MARKET CAP
25.70M
P/E (TTM)
35.00
1D
5D
1M
3M
1Y
5Y
1D
XOMA Royalty: Preferreds Still Offer Compelling Income Despite Call Risk
Seeking Alpha · 2d ago
XOMA Royalty Completes Acquisition of Generation Bio for $4.29 Per Share
Reuters · 3d ago
XOMA Royalty übernimmt Generation Bio für 4,29 Dollar je Aktie
Reuters · 3d ago
Weekly Report: what happened at XOMAP last week (0202-0206)?
Weekly Report · 3d ago
XOMA Royalty Corporation veröffentlicht ergänzten Bericht zu LAVA-Legacy-Assets
Reuters · 02/02 21:34
XOMA Royalty Corporation Issues Amendment to Report on LAVA Legacy Assets
Reuters · 02/02 21:34
Weekly Report: what happened at XOMAP last week (0126-0130)?
Weekly Report · 02/02 09:54
Weekly Report: what happened at XOMAP last week (0119-0123)?
Weekly Report · 01/26 09:54
More
About XOMAP
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.

Webull offers XOMA Royalty Corp stock information, including NASDAQ: XOMAP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XOMAP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XOMAP stock methods without spending real money on the virtual paper trading platform.